about
Nintedanib in NSCLC: evidence to date and place in therapyStabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Improvement in lung cancer outcomes with targeted therapies: an update for family physiciansExosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practiceALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome itCancer and the microbiome: potential applications as new tumor biomarker.Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus.Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?Liquid biopsies in lung cancer: the new ambrosia of researchers.Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?A headlight on liquid biopsies: a challenging tool for breast cancer management.Dietary restriction: could it be considered as speed bump on tumor progression road?Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.Hypoxia and human genome stability: downregulation of BRCA2 expression in breast cancer cell lines.EGFR inhibition in NSCLC: New findings…. and opened questions?Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool.Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis.Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysisSpheroids from adipose-derived stem cells exhibit an miRNA profile of highly undifferentiated cellsMonitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patientsAdipose tissue, angiogenesis and angio-MIR under physiological and pathological conditionsAn update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapyHereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes
P50
Q26745424-06053EE3-C70C-475C-AFA9-128C2C523C3DQ26781365-3E73F6F6-065C-4694-9727-303C45D63F4BQ26796348-2E2AF35B-D87B-4CFB-A11D-8E020A601743Q26824519-B5389323-5BF2-4B50-8E63-DA21BD77358AQ28066211-57740D0E-85F0-4EE3-B3CC-184FD8AA5485Q28083386-6BAEE445-C7FB-4CC1-96E5-EC668AF08258Q35508820-BC4451E0-9942-4ACE-874D-5AD805990DC4Q37565288-1D7FAA91-F37D-4E42-9648-9B31E8174595Q37645090-1C4A42B9-3955-4795-9D53-B131E16C4459Q38138237-914289FE-7BA7-4F4C-A52D-2250BBE1BD2FQ38242271-51DC54F6-F9D4-4F5B-A376-0B6DA9545F7DQ38274719-FC20B74D-78CD-4E90-81C5-B72E309FF2E6Q38584814-6435CC1B-AB12-4328-8D83-0354018216CCQ38704258-C1C1A4FF-14D5-4277-B787-87DEC7C68BF3Q38797885-F102CFA6-AE2D-42ED-B870-027035F09F42Q38826542-160F5554-05B0-44FA-98CB-D9ECCE945A41Q39068877-A6794304-79B6-47A1-80B8-815E5C84113AQ39191212-EF5406C2-0516-4E60-8200-58C2B9612ACCQ39693752-4D40D7BF-0DAC-4A07-8B5C-3FC41CC06DE2Q53703482-F9787D66-DCBB-41ED-B4B2-F6D4861CD92DQ59335739-F533EB35-62D3-4E54-9E14-021ADA5B5AA8Q60194596-A6F99A6E-F89B-4C2A-8349-FAAE7A51FF62Q64111039-4205CE82-08EF-4700-B08E-008B7B3C5782Q90348728-C4B4899D-66AE-4062-9B8F-C3802F556F43Q91817890-B1EFFA62-9396-4EEA-A793-47E9E743D774Q94542892-2FB5E317-F985-4579-8A9B-72480E92CA4A
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Marta Castiglia
@en
Marta Castiglia
@nl
type
label
Marta Castiglia
@en
Marta Castiglia
@nl
prefLabel
Marta Castiglia
@en
Marta Castiglia
@nl
P31
P496
0000-0002-6299-7235